Clinical trial NCT02057315: Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
Official title: A Randomized, Double-Blind, Cross-Over, Placebo-Controlled Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Migraine Headaches
Keywords: Migraine headache
Photophobia
Phonophobia
Aura
Topical treatment
Lead sponsor: Achelios Therapeutics
Sponsor class: INDUSTRY
First posted: 2014-02-07
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65 years that suffer recurring moderate-severe migraine headaches (2-8 per month).

This study is designed to describe the efficacy and safety of ELS-M11 as compared to placebo.

Detailed description: Achelios is developing ELS-M11 for topical application for the acute treatment of migraine events in patients with a history of migraine with or without aura.

To be eligible for the study, patients must have a one-year documented history of migraine headache (as defined by the International Headache Society IHS), with or without aura, with 2≤8 moderate or severe migraine attacks per month in the 2 months prior to the screening visit.

The total duration of the study is the completion of five migraine headaches per subject over a maximum 12 week period followed by a 3-14 day Follow-Up Period.

Eligibility criteria: Inclusion Criteria:

* Provide written informed consent
* Males and females aged 18-65 who can read, write and understand English
* Subject has at least a one year documented history of migraine headache (defined by International headache Society IHS) migraine definitions, with or without aura, with 2≤8 moderate or severe migraine attacks per month in the 2 months prior to the screening visit
* Is stable on the current standard non-opioid rescue medication for at least 2 months prior to randomization
* Can distinguish migraine from tension headache (HA), with 24 hours of freedom from HA between migraine events
* Women of childbearing potential must be currently using or willing to use contraception (30 days prior to start of study medication and for 21 days after taking study medication)
* Women of non-childbearing potential include females regardless of age, with functioning ovaries and who have a current documented tubal ligation \[Hatcher, 2004\] bilateral oophorectomy or total hysterectomy, or post-menopausal females
* The subject is able and willing to perform the assessments and procedures as specified in this protocol, including the ability to learn and follow instructions for ePRO device

Exclusion Criteria:

* Migraineurs taking opioid-based rescue medications for any indication
* Subject has history of mild migraine events or migraines that usually resolve spontaneously in less than 2 hours
* Subject has menstrual migraines
* Positive Drug Test
* Subject has basilar or hemiplegic migraines
* Subject has more than 15 headache-days per month
* Subjects with a history of facial allodynia
* Subject has a history of vomiting during more than 30% of migraine episodes
* Self confinement to bed rest for more than 50% of migraine episodes
* Subject was greater than 50 years old at age of migraine onset
* Acute coronary syndrome (i.e., myocardial infarction and unstable angina), stroke or resuscitated cardiac arrest within the past 3 months
* Severe congestive heart failure
* Systolic blood pressure (sBP) \>160 mmHg or diastolic blood pressure (dBP) \>100 mmHg measured in the sitting position at Visit 1
* Current active renal disease
* Any history of pyelonephritis
* Evidence of active liver disease
* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase \>2 times the upper limit of the reference range (ULRR), or total bilirubin \>1.5 times the ULRR at Visit 1
* Past history of acute pancreatitis with current triglycerides 4.56 mmol/L (400 mg/dL) at Visit 1
* History of malignancy within the past 3 years, other than non-melanoma skin cancer (i.e., basal or superficial squamous cell carcinoma) and treated cervical cancer in-situ
* Any planned major surgery to be performed during the study (e.g., coronary artery bypass surgery, abdominal aortic aneurysm repair, etc.)
* Current life-threatening condition
* Significant hypersensitivity to NSAIDs (e.g., difficulty swallowing or breathing, tachycardia, anaphylaxis, angioedema or skin reaction)
* Pregnancy (defined by positive urine pregnancy test) or lactation at Visit 1, or planning to become pregnant prior to completion of the study
* History or suspicion of alcohol or substance abuse (current or past 6 months).
* Participation in any clinical trial within 30 days prior to Visit 1
* Subjects with a history of hypersensitivity to products containing tiaprofenic acid, suprofen, fenofibrate, oxybenzone, or octocrylene (e.g., sunscreen, perfume)
* Subjects with a history of photosensitivity
* Any clinically significant abnormality or any reason that the subject may not be able to complete the full study observational period

Primary outcomes:
measure: Percentage of patients who experience pain relief 2 hours following the first application of ELS-M11
timeFrame: 2 hours
Secondary outcomes:
measure: Percentage of patients who report pain relief at various time points within a 24 hour period, following the first application of ELS-M11
timeFrame: 24 hours
measure: Percentage of patients who report complete pain resolution within 24 hours following the first application of ELS-M11.
timeFrame: 24 hours
measure: Percentage of patients who report sustained pain relief after the first application of ELS-M11
timeFrame: 24 hours
measure: Percentage of patients who report sustained complete pain resolution after the first application of ELS-M11.
timeFrame: 24 hours
measure: Time to Initial Use of Rescue Medication following the first application of ELS-M11
timeFrame: 24 hours
measure: Use of Rescue Medication following the first application of ELS-M11 by 24 hours
timeFrame: 24 hours
measure: Resolution of migraine-associated symptoms, following the first application of ELS-M11
timeFrame: 24 hours
measure: Percentage of patients who can resume or maintain their normal routine, following the first application of ELS-M11.
timeFrame: 24 hours
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Michigan Head Pain and Neurological Institute
state: Michigan
city: Charleston
country: United States
facility: Coastal Carolina Research Center
state: South Carolina
Study officials:
affiliation: Achelios Therapeutics, Inc.
name: Crist J. Frangakis, Ph.D.
role: STUDY_CHAIR
References: